FOR IMMEDIATE RELEASE
ZeevieZee BioPharma Announces Strategic Clinical Development Milestones: Gastro‑Protected Aspirin Formulation and Oral Mucositis Lozenge Candidate
New aspirin formulation with integrated gastroprotection to enter clinical testing in Q4 FY2026–27; oral mucositis lozenge candidate to commence clinical trials in Q1 FY2027–28
ZeevieZee BioPharma, a [brief descriptor, e.g., clinical‑stage biopharmaceutical company focused on innovative drug delivery and patient‑centric formulations], today announced key milestones in its clinical development pipeline. The company plans to initiate clinical testing of a new gastro‑protected aspirin formulation in the fourth quarter of fiscal year 2026–27, and to commence clinical trials of its pipeline candidate for the management of oral mucositis, delivered as an oral lozenge, in the first quarter of fiscal year 2027–28.
Gastro‑protected aspirin formulation
Chronic use of aspirin, while beneficial for cardiovascular protection and pain management, is associated with gastrointestinal (GI) irritation and mucosal injury. ZeevieZee’s new formulation is designed to retain the therapeutic benefits of aspirin while incorporating gastroprotective features intended to reduce GI adverse effects.
Key points:
- Indication focus: Secondary prevention of cardiovascular events and/or analgesic/anti‑inflammatory use (as per final labeling strategy).
- Differentiation: Integrated gastroprotection within the aspirin dosage form, aiming to improve tolerability and adherence in patients requiring long‑term therapy.
- Development timeline: Clinical testing is planned to begin in Q4 FY2026–27, starting with early‑phase studies to evaluate safety, tolerability, and pharmacokinetic profile, followed by subsequent efficacy‑focused trials.
Oral mucositis lozenge candidate
Oral mucositis is a common and painful complication of cancer therapy, particularly in patients receiving chemotherapy and/or radiation for head and neck cancers. Effective, easy‑to‑use local therapies remain an important unmet need.
ZeevieZee’s pipeline candidate for oral mucositis is being developed as an oral lozenge, designed to provide localized symptom relief and/or mucosal protection. The company plans to commence clinical trials in Q1 FY2027–28.
Key points:
- Target population: Patients with cancer therapy–associated oral mucositis (e.g., head and neck cancer patients undergoing radiotherapy/chemotherapy).
- Dosage form: Oral lozenge for convenient, patient‑friendly administration.
- Development timeline: First‑in‑human/early clinical studies expected to start in Q1 FY2027–28, with subsequent trials to assess efficacy, safety, and impact on pain and quality of life.
Leadership commentary
“These milestones reflect our commitment to developing differentiated, patient‑friendly formulations that address real clinical challenges,” said Research scholars of ZeevieZee BioPharma. “Our gastro‑protected aspirin aims to improve the safety and tolerability profile of a widely used medicine, while our oral mucositis lozenge targets a painful and often undertreated complication of cancer therapy.”
“By advancing these programs through carefully designed clinical studies, we aim to generate robust evidence that can support meaningful improvements in patient care.
About ZeevieZee BioPharma
ZeevieZee BioPharma is a [brief company description: e.g., biopharmaceutical company focused on novel drug delivery systems and differentiated formulations in therapeutic areas including cardiology, oncology supportive care, and pain management]. The company’s pipeline combines established pharmacological agents with innovative formulation technologies to enhance efficacy, safety, and patient experience.
Forward‑looking statements
This press release contains forward‑looking statements regarding ZeevieZee BioPharma’s development plans, including anticipated timelines for clinical trials and the potential benefits of its product candidates. These statements are based on current expectations and are subject to risks and uncertainties, including regulatory, clinical, and commercial risks. Actual results may differ materially from those expressed or implied by these statements. ZeevieZee BioPharma undertakes no obligation to update these forward‑looking statements except as required by law.